biorad genetic systems hiv  (Bio-Rad)

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Article Title: Performance of the Alere Determine ™ HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast

doi: 10.1016/j.jcv.2013.07.002

Figure Lengend Snippet: Sensitivity of assays reactivity during early HIV-1 infections relative to number of days before first positive WB. The names, abbreviations, and sources, of the HIV assays are as follows [4]: APTIMA HIV-1 Quantitative assay (Aptima, Gen-Probe, Inc., San Diego, CA); ARCHITECT® HIV Ag/Ab Combo assay (Architect; Abbott Diagnostics, Wiesbaden Germany; CE marked version was used as the US version was not available when testing was conducted); GS HIV-1/2 Combo Ag/Ab (BioRad Combo; Bio-Rad Laboratories, Redmond, WA); GS HIV-1/HIV-2 Plus O EIA (GS + O; Bio-Rad Laboratories, Redmond, WA); VITROS anti-HIV 1+2 assay (Vitros; Ortho-Clinical Diagnostics, Buckinghamshire, UK); ADVIA Centaur HIV 1/O/2 enhanced assay (Advia; Bayer, Tarrytown, NY); Abbott HIVAB HIV-1/HIV-2 (rDNA) EIA (Abbott; Abbott Laboratories, Abbott Park, IL); Avioq HIV-1 Microelisa system (Avioq; Avioq, Inc, Rockville, MD); Multispot HIV-1/HIV-2 rapid test (Multispot; Bio-Rad Laboratories); Clearview HIV-1/2 STAT-PAK (Statpak; Inverness Medical, Princeton, NJ); Clearview COMPLETE HIV-1/2 (Complete; Inverness Medical); Reveal G2 and G3 Rapid HIV-1 antibody tests (Reveal G2 or G3; MedMira Laboratories, Inc.; Halifax, Nova Scotia, Canada); OraQuick ADVANCE Rapid HIV-1/2 antibody test (Oraquick; OraSure Technologies, Inc.; Bethlehem, PA); Uni-Gold Recombigen HIV (Unigold; Trinity Biotech USA, St. Louis, MO). These assays have manufacturer reported point estimates for sensitivity ranging from 99.60% to 100.00% and point estimates for specificity ranging from 98.60% to 99.90%. The Genetic Systems HIV-1 Western blot (WB; Bio-Rad Laboratories) and Cambridge Biotech HIV-1 Western blot (WB; Maxim Biomedical Inc., Rockville, MD) have been shown to give concordant interpretations in studies conducted to qualify use in our clinical laboratory and were used interchangeably. ind: indeterminate.

Article Snippet: The Genetic Systems HIV-1 Western blot (WB; Bio-Rad Laboratories) and Cambridge Biotech HIV-1 Western blot (WB; Maxim Biomedical Inc., Rockville, MD) have been shown to give concordant interpretations in studies conducted to qualify use in our clinical laboratory and were used interchangeably. ind: indeterminate. . 4.1.2.

Techniques: Western Blot

Journal: iScience

Article Title: Development of a multiassay algorithm (MAA) to identify recent HIV infection in newly diagnosed individuals in Indonesia

doi: 10.1016/j.isci.2023.107986

Figure Lengend Snippet: DNA sequencing strategy of the HIV pol gene The sequencing strategy covers the HIV-1 pol gene that consists of protease (PR) amino acids 1–99, reverse transcriptase (RT) amino acids 1–560, and integrase (IN) amino acids 1–288. NFLG cDNA was synthesized in two separate reactions, each using the GSPs Pan-HIV 1F or Pan-HIV 4R. Pre-sequencing amplification was done using both cDNAs as templates in nested amplification. The target region was initially amplified in two large fragments, using primer set 1 that covers HXB2 1031–5308 (4278-bp) and primer set 2 that covers HXB2 2030–4604 (2575-bp). Amplicon 1 was re-amplified into 4 overlapping fragments: F0 (1031–2682), F1 (2030–3817), F2 (2519–4604), and F3 (2984–5308) whereas amplicon 2 was re-amplified into 3 overlapping fragments: FA (2519–3817), FB (2030–3410), and FC (2984–4604). All fragments were sequenced using several overlapping primers, 8 primers each for F0 – F3 and 6 primers each for FA – FC ( Table S3 ).

Article Snippet: It has been validated for avidity analysis among ARV naive samples in an evaluation panel containing CRF01_AE, with AI 0 · 7 as the optimized threshold ; with performance comparable to the Genetic Systems HIV-1/HIV-2 Plus O EIA [Bio-Rad, Marnes-la-Coquette, France] that have been established for avidity-based recency test.

Techniques: DNA Sequencing, Sequencing, Synthesized, Amplification

Journal: PLOS Global Public Health

Article Title: Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants

doi: 10.1371/journal.pgph.0002037

Figure Lengend Snippet: VISP/R rate per diagnostic assay.

Article Snippet: BioRad Genetic Systems HIV 1/2 Plus O EIA , 2006–2013 , UWVSL , , 43% , , 0% , , 100% , 79% , 66% , , , 96% , 47%.

Techniques: Diagnostic Assay, Western Blot, Confirmatory Assay